CORONAVIT was a phase 3 randomized controlled trial, investigating the potential of vitamin D to reduce incidence and severity of acute respiratory infections (ARI) and COVID-19. touchRESPIRATORY were delighted to speak with Professor Adrian Martineau (Queen Mary University of London, London, UK) to learn more around the aims, design and outcome measures of the phase 3 CORONAVIT study and why vitamin D replacement failed to reduce risk of all-cause ARI or COVID-19 in this study.
The abstract ‘Vitamin D to prevent COVID-19 or other acute respiratory infections: phase 3 randomised controlled trial (CORONAVIT).’ (Abstract number: OA3795) was presented at ERS 2022, 4–6 September, 2022.
- What is known about the impact of vitamin D status on susceptibility to acute respiratory infections (ARI)? (0:11)
- What were the aims, design and eligibility criteria of your study? (1:14)
- What were the outcome measures of the study and how well were they achieved? (1:54)
- Why do you think that vitamin D replacement failed to reduce risk of all-cause ARI or COVID-19 in this study? (2:51)
- What questions remain unanswered and what future studies are planned? (4:05)
Disclosures: Adrian Martineau discloses receiving grant/ research support from Barts Charity (ref. MGU0459), Pharma Nord Ltd, the Fischer Family Foundation, DSM Nutritional Products Ltd, the Exilarch’s Foundation, the Karl R Pfleger Foundation, the AIM Foundation, Synergy Biologics Ltd, Cytoplan Ltd, the UK National Institute for Health Research Clinical Research Network, the HDR UK BREATHE Hub, Thornton & Ross Ltd, Warburtons Ltd, Mr Matthew Isaacs (personal donation), and Hyphens Pharma Ltd; serving on advisory boards for Qiagen Ltd; and receiving honoraria from DSM Nutritional Products Ltd, Linus Pauling Institute.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ERS meeting 2022.
Share this Video
Related Videos In COVID-19
Margaret Pisani, Research highlights in COVID-19 from 2022
Longitudinal studies into the long-term impact of COVID-19 are currently at the forefront of research, touchRESPIRATORY interviewed editorial board member Prof. Margaret Pisani (Yale School of Medicine. New Haven, CT, USA) about what to look out for in 2023 in this area. Disclosures: Margaret Pisani has nothing to disclose in relation to this video interview. Support: Interview and filming […]
Alan Kaplan: IPCRG COVID-19 and Respiratory Q&A – COVID-19 Controversies, Vaccination and Booster Doses
The IPCRG COVID-19 and Respiratory Q&A is providing evidence based COVID and respiratory advice to practising primary care clinicians. Prof. Alan Kaplan (University of Toronto, Toronto, ON, Canada) answers questions from the Q&A on managing COVID-19, how to address the controversies surrounding the COVID-19 vaccines, and the immunity provided from COVID-19 vaccination and booster doses. […]
Fiona Mosgrove: IPCRG COVID-19 and Respiratory Q&A – a Focus on COVID-19
touchRESPIRATORY caught up with Dr Fiona Mosgrove (University of Aberdeen Medical School, Aberdeen, Scotland) to discuss the COVID-19 and respiratory Q&A created by IPCRG and to answer some of the key questions around the variants of SARS-CoV-2, treatments for COVID-19 and what will happen as we move out of the pandemic. Questions Could you give […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!